RespireRx Pharmaceuticals — BIO CEO & Investor Conference 2017
38 slides from RespireRx Pharmaceuticals's conference presentation, Feb 10, 2017
Slide 1: RespireRx Pharmaceuticals: Medicines for Respiratory Diseases
R RespireRx Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO BIO CEO & Investor Conference New York, February 13, 2017 Medicines for Respiratory Diseases
Slide 2: Forward Looking Statements
Forw. Looking Statements WD The matters discussed in this presentation that are not historical facts are "forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that such forward-looking statem
Slide 3: Breath quote
Breath WN RespireRx "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." bene Abbot George Burke
Slide 4: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases Ao RespireRx Pharmaceuticals Inc Cannabinoids — Dronabinol - Phase 3 ready for Obstructive Sleep Apnea (OSA) Ampakines — CX1739 & CX717 — 4 successful Phase 2A proof of concept trials for Central Sleep Apnea (CSA) and opioid induced respiratory depressio
Slide 5: Sleep Apnea: A National Health Epidemic
Sleep Apnea A National Health Epidemic
Slide 6: Sleep Apnea: A National Health Epidemic
Sleep Apnea: A National Health Epidemic dQ Respil pireRx Over 35 Million Americans Stop Breathing Every Night From 5 — 50 Times Per Hour This Is Not Merely Snoring
Slide 7: Sleep Apnea and its Measurement
Sleep Apnea and its Measurement >) RespireRx Pharmaceuticals Inc Apnea — Cessation of breathing for > 10 seconds Hypopnea - Abnormal severe slowing of breathing for > 10 seconds Apnea - Hypopnea Index (AHI) — An indicator of the severity of sleep apnea. AHI is the average number of apnea- hypopnea e
Slide 8: Three Types of Sleep Apnea
Three Types of Sleep Apnea A) RespireRx Pharmaceuticals Inc * Obstructive (OSA) - a peripheral phenomenon that occurs when throat muscles intermittently relax and block airway during sleep. OSA may be accompanied by snoring * Central (CSA) - a brain-mediated phenomenon that occurs when breathing con
Slide 9: Company Focus: Apneas
Company Focus: Apneas Gd RespireRx ¢ Dronabinol for Obstructive Sleep Apnea e Ampakines to address: Post-surgical Central Sleep Apnea Chronic CSA Spinal Cord Injury Related Apnea
Slide 10: Respiratory Diseases Product Pipeline
RespireRx eee se Inc Respiratory Diseases Product Pipeline [yy Compound | Indication Preclinical Phase 1 Phase 2 Dronabinol | PbSMuctive Sleep ee Apnea Chronic CSA ——_—_—— CX1739 Postsugicel ch | > Opicidinduced RO | TS CX717 Spinal Cord Injury ———— CX1942 -i rae euiced RD — 10
Slide 11: Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea
Dronabinol: Breakthrough Treatment for Obstructive Sleep Apnea ee Pharmaceuticals Inc 11
Slide 12: Obstructive Sleep Apnea: Epidemiology
Obstructive Sleep Apnea: Epidemiology ARespireRx Pharmaceuticals Inc U.S Adult Population 245.2M 12% Prevalence OSA (AHI>5) 29.4M 80% 20% Undiagnosed Diagnosed 23.5M 5.9M _ oT Source: Primary research withexpers US, Census (2014), Peppard "Increased Prevalence ofleepdsordered Breathingin Adu" © amer
Slide 13: OSA - Costs of the Problem in the US
OSA - Costs of the Problem in the US (Resp pireRx Pharmaceuticals Inc Estimated Annual Indicated US Annual Costto Drug Therapy Disease State Prevalence US Economy Expenditures OsaA's 29.4 Million $162.0 Billion $0 Asthma®7 16.4 Million $18.3 Billion $13.5 Billion Hypertension®° 43.2 Million $73.4 Bi
Slide 14: Dronabinol is Δ9-THC
Dronabinol is A9-THC Oral, small molecule Cannabinoid receptor agonist Reduces apnea by acting on spinal ganglia controlling muscle tone in throat Positive Phase 2A and 2B clinical trials in OSA gh Treatment OSA >) RespireRx Pharmaceuticals Inc Dronabinol Background = FDA approved for the treatment
Slide 15: No Approved Medicines Exist for OSA
No Approved Medicines Exist for OSA WR Current Approved Treatments CPAP device Surgery Dental devices Implant nerve stimulator Exercises Stimulants for next day sleepiness CPAP is the Standard Treatment for OSA * 30% of patients prescribed CPAP never initiate treatment PAROS * Over 50% of patients s
Slide 16: Successful Phase 2B PACE Trial in OSA
Successful Phase 2B PACE Trial in OSA (O RespireRx - Six week, double-blind, placebo controlled clinical study in patients with OSA - Doses: Placebo, 2.5 mg and 10 mg at night - Conducted by University of Illinois at Chicago and Northwestern University - Fully funded by NIH - >$5 million 16
Slide 17: Successful Phase 2B PACE Trial in OSA
Successful Phase 2B PACE Trial in OSA ®)RespireRx * 56 evaluable patients completed study = Placebo, n = 17 = 2.5 mg dronabinol, n = 19 = 10 mg dronabinol, n = 20 * Results revealed a statistically significant improvement in Primary Outcome Measures: » Apnea-Hypopnea Index (AHI) (2.5 and 10 mg)! = E
Slide 18: PACE Phase 2B Clinical Trial: OSA After Weeks of Dronabinol Treatment
PACE Phase 2B Clini | Trial: OSA After 6 Weeks of Dronabinol Treatment Apnea-Hypopnia Index (AHI) Placebo i p=.02 d 7 2.5 mg 10mg RespireRx Pharmaceuticals Inc 18
Slide 19: PACE Phase 2B Trial Compared to Phase 2A
PACE Phase 2B Trial Compared to Phase 2A (d)Resp pireRx Pharmaceuticals Inc ** p<.02, compared to placebo for Phase 2A ae Phase 2A* PACE Phase 2B Placebo 2.5mg 10 mg Apnea-Hypopnia Index (AHI) * Double blind, placebo controlled dose-ascending study in patients with OSA, n=19 19
Slide 20: Dronabinol Phase 3 Regulatory Strategy
Dronabinol — Phase 3 Regulatory Strategy (O RespireRx - Meet with FDA during H1/2017 - Finalize the Phase 3 trial plan required for approval - Agree on a Special Protocol Assessment (‘SPA’) - Position dronabinol as a breakthrough medicine - Seek fast track designation - Facilitate and hasten the dev
Slide 21: Protecting Dronabinol in the Market
Protecting Dronabinol in the Market dQ RespireRx Method-of-Use patent for dronabinol in OSA - Expires in 2025 Schedule III drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label Off-label use of generics and medical marijuana are not covered by insu
Slide 22: The Dronabinol Opportunity
The Dronabinol Opportunity )RespireRx Impact on Patient Commercial Potential First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular outcomes Changes the nature of OSA treatment Broadly expands prescriber base from sleep
Slide 23: Potential Dronabinol Economics
Potential Dronabinol Economics >) RespireRx lf FDA approves dronabinol for the treatment of OSA: * Initial target market: Mild to moderate OSA patients who are diagnosed but do not use CPAP * 1,770,000 adults (i.e., 30% of 5.9 million diagnosed adults). * Daily price per pill is $5.00 * Patient comp
Slide 24: Ampakines for Opioid Induced Apneas
Ampakines for Opioid Induced Apneas 24
Slide 25: Chronic Opioid Use and Central Sleep Apnea
ic Opioid Use and Central Sleep Apnea (Ad RespireRx Pharmaceuticals Inc Opioid Epidemic U.S. pharmacies annually dispense 245 million Rx for opioid pain relievers 10 - 11 million patients in the US on chronic opioid therapy for pain Opioid induced respiratory depression is manifested as CSA >50% of
Slide 26: Post-surgical Central Sleep Apnea: Outcomes
Post-surgical Central Sleep Apnea: Outcomes Gd RespireRx Pharmaceuticals Inc Length of Stay (days) Mortality Rate (%) Hospital Costs ($ 20 18 billions) 10 10 *” x : al With Respiratory Without Respiratory Depression Depression WiliRespliaionyy §—_WWithbbt: With Respiratory Without Respiratory Depres
Slide 27: Ampakines for CSA
Ampakines for CSA >) RespireRx Pharmaceuticals Inc Current CSA Treatments « No medicine or device is approved for CSA ¢ CPAP is contra-indicated Ampakines for CSA * Post-surgical CSA produced by opioid pain management Short term use (<1 week) * CSA caused by opioid use in patients with chronic pain
Slide 28: Translational Approach to Respiratory Disorders
Translational Approach to Respiratory Disorders (®Q RespireRx \ = Brain stem nuclei that regulate breathing contain opiate and AMPA _ glutamate receptors that inhibit and excite cell activity, respectively = Ampakines act as_ positive, allosteric modulators of the AMPA-type glutamate receptor to enh
Slide 29: Development Status of the Ampakines
Development Status of the Ampakines Ad RespireRx Pharmaceuticals Inc * CX1739 = Successfully completed four Phase 1 Safety Trials = Successfully completed Phase 2A Trial in opioid-induced respiratory depression = Successfully completed Phase 2A Trial in CSA * CX717 = Successfully completed multiple
Slide 30: Ampakines Reduce Opioid Induced Respiratory Depression in Phase 2A Trials
RespireRx eaten Inc Ampakines Reduce Opioid Induced Respiratory Depression in Phase 2A Clinical Trials i= Sy @s 23 £3 EB 2 af rae J! go ag ee 45 2s 26 of 2 A re Ampakines reduce opioid induced respiratory Placebo x717 Placebo CX1739 1500 mg 900 mg p<.01 ps1 depression without altering analgesia 30
Slide 31: Ampakine Indications and IP
Ampakine Indications and IP GQ RespireRx Pharmaceuticals Inc * Targeted Indications * Post-surgical, opioid-induced CSA * Chronic CSA * Spinal cord injury = Combination formulation with an opioid for treatment of chronic pain * Intellectual Property Protection (owned and licensed) = Issued Compositi
Slide 32: Summary
Summary as Pharmaceuticals Inc 32
Slide 33: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline ()Resp pireRx Pharmaceuticals Inc Compound | Indication Preclinical Phase 1 Phase 2 Dronabinol | PbSMuctive Sleep ee Apnea Central Sleep Apnea ———— CX1739 Post-surgical Apnea Op Opioid-incuced RO | CX717 Spinal Cord Injury ey cx1942 Drug-induced RD —/ (injectabl
Slide 34: Development Milestones
Development Milestones A) RespireRx Pharmaceuticals Inc 1Q2017 202017 3Q2017_ —-4Q2017_ — 12018 —- 22018 Dronabinol FDA Regulatory - Prepare and submit SPA Pivotal Clinical Trial Proprietary Extended Release Formulation Development X1739 FDA Regulatory - Prepare and submit IND Central Sleep Apnea Cl
Slide 35: Capital Structure and Market Metrics
Capital Str ture and Market Metrics Go RespireRx Pharmaceuticals Inc Pro Forma at January 31, 2017 Common Stock (includes 130,000 shares issued on Dec 29 and 30, 2,149,000 2016 Common Stock Equivalents of Convertible Notes 30,000 Common Stock Equivalents of all Options and Warrants Granted (includes
Slide 36: Management and Directors
ent and Directo Gd RespireRx Pharmaceuticals Inc James Manuso President, CEO & Vice Chairman Arnold Lippa CSO & Executive Chairman Jeff Margolis VP, Secretary/Treasurer, Director Robert Weingarten CFO, Director Richard Purcell Senior VP, R& D Katie MacFarlane Director Senior VP, Napo Pharmaceuticals
Slide 37: Innovative Medicines for Respiratory Diseases
Innovative Medicines for Respiratory Diseases Ao RespireRx Pharmaceuticals Inc Cannabinoids — Dronabinol - Phase 3 ready for Obstructive Sleep Apnea (OSA) Ampakines — CX1739 & CX717 — 4 successful Phase 2A proof of concept trials for Central Sleep Apnea (CSA) and opioid induced respiratory depressio
Slide 38: James S. Manuso, Ph.D., President & CEO
R RespireRx Pharmaceuticals Inc James S. Manuso, Ph.D., President & CEO BIO CEO & Investor Conference New York, February 13, 2017 Medicines for Respiratory Diseases
RespireRx Pharmaceuticals — BIO CEO & Investor Conference 2017 on 6ix